Swedish company TikoMed announces successful outcome of phase II safety trial on patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections
Press release follows here: TikoMed announces the publication of results from an open-label, single arm, single center phase II trial carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics and Biomarkers (D3B) team in patients with confirmed Amyotrophic Lateral Sclerosis (ALS) treated with weekly ILB® injections. The trial outcomes demonstrated that: · Long-term weekly ILB® injections of 2 mg/kg were well tolerated, had minimal side-effects and had an acceptable safety profile in all the 11 patients · ALSFRS-R